Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Thermo Fisher Scientific, Danaher, Yourgene, and More

NEW YORK – Thermo Fisher Scientific said this week that it has been awarded a $192.5 million contract from the US Department of Defense to ensure reliable domestic production of pipette tips for use within research and diagnostic labs. Using this award, the company said it will co-invest with the US government in building a new, state-of-the-art, energy efficient manufacturing facility for pipette tips in North Carolina. Construction will be fully completed by Q3 2024, with pipette tip manufacturing starting as early as Q3 2023.

Danaher said this week that it has completed its $9.6 billion acquisition of Aldevron, which will operate as a standalone company under Danahers life sciences segment. Danaher announced the acquisition in June and said on a conference call in July that it expects the company to generate $500 million in revenues in 2022. Fargo, North Dakota-based Aldevron manufactures plasmid DNA, mRNA, and proteins for biotechnology and pharmaceutical customers in research, clinical, and commercial applications. 

Yourgene said this week that it has received ISO 15189:2012 accreditation for its COVID-19 testing and sequencing services, following assessments by the UK accreditation service. The company said this accreditation provides assurance that itCitylabs 1.0 laboratory in Manchester meets internationally recognized standards of performance and competence.

AnPac Bio-Medical Science said this week that its clinical laboratory in Philadelphia has received accreditation from the College of American Pathologists. The company has operations in the US and China. 

Revelation Biosciences, a San Diego-based firm developing therapeutics and diagnostics for respiratory diseases, said this week that it has signed a definitive merger agreement with Petra Acquisition, a special purpose acquisition company, which will result in Revelation becoming a publicly traded firm. The merged firm will use $73 million in gross proceeds from a Petra Acquisition trust account to support continued development of an immune-boosting drug, REVTx-99, for respiratory viral infections, as well as for continued development of a rapid, point-of-care diagnostic for respiratory viral infections. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx. 

Filed under